Abstract:Cytotoxic accumulation of loosely bound mitochondrial Fe 2+ is a hallmark of Friedreich's Ataxia (FA), a rare and fatal neuromuscular disorder with limited therapeutic options. There are no clinically approved medications targeting excess Fe 2+ associated with FA or the neurological disorders Parkinson's disease and Multiple System Atrophy. Traditional iron-chelating drugs clinically approved for systemic iron overload that target ferritin-stored Fe 3+ for urinary excretion demonstrated limited efficacy in FA and exacerbated ataxia. Poor treatment outcomes reflect inadequate binding to excess toxic Fe 2+ or exceptionally high affinities (i.e. ≤10 -31 ) for non-pathologic Fe 3+ that disrupts intrinsic iron homeostasis. To understand previous treatment failures and identify beneficial factors for Fe 2+ -targeted therapeutics, we compared traditional Fe 3+ chelators deferiprone (DFP) and deferasirox (DFX) with additional iron-binding compounds including ATH434, DMOG, and IOX3. ATH434 and DFX had moderate Fe 2+ binding affinities ( K d 's of 1-4 μM), similar to endogenous iron chaperones, while the remaining had weaker divalent metal interactions. These compounds had low/moderate affinities for Fe 3+ (0.46-9.59 μM) relative to DFX and DFP. While all compounds coordinated iron using molecular oxygen and/or nitrogen ligands, thermodynamic analyses suggest ATH434 completes Fe 2+ coordination using H 2 O. ATH434 significantly stabilized bound Fe 2+ from ligand-induced autooxidation, reducing reactive oxygen species (ROS) production, whereas DFP and DFX promoted production. The comparable affinity of ATH434 for Fe 2+ and Fe 3+ position it to sequester excess Fe 2+ and facilitate drug-to-protein iron metal exchange, mimicking natural endogenous iron binding proteins, at a reduced risk of autooxidation-induced ROS generation or perturbation of cellular iron stores. Graphical Open in new tabDownload slide

In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics

A DFX-based iron nanochelator for cancer therapy

Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties

The effect of the iron chelator Deferasirox in combination with Cisplatin chemotherapy against lung carcinoma

Deferasirox's Anti-Chemoresistance and Anti-Metastatic Effect on Non-Small Cell Lung Carcinoma

Abstract 3898: Synergistic combination of the iron chelator deferasirox with cisplatin and doxorubicin chemotherapies against nonsmall cell lung carcinoma

Mitochondrially targeted deferasirox kills cancer cells simultaneous iron deprivation and ferroptosis induction

Deferasirox-TAT(47–57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine

Tuning the Solid- and Solution-State Fluorescence of the Iron-Chelator Deferasirox

New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis

Deferasirox (ExJade): A Fluorescent Pro-Chelator Active Against Antibiotic Resistant Bacteria

ATH434, a promising iron-targeting compound for treating iron regulation disorders

Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination

Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment: in-vitro and in-vivo evaluation

An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells

Antioxidant targeting by deferiprone in diseases related to oxidative damage

1,3,5-Triaza-7-phosphaadamantane and Cyclohexyl Groups Impart to Di-Iron(I) Complex Aqueous Solubility and Stability, and Prominent Anticancer Activity in Cellular and Animal Models

Design, synthesis and evaluation of novel deferasirox derivatives with high antifungal potency in vitro and in vivo

A Comparative Study on the Complexation of the Anticancer Iron Chelator VLX600 with Essential Metal Ions

Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy

2D-ultrathin MXene/DOXjade platform for iron chelation chemo-photothermal therapy